quintiles and imshealth have merged together to form the new quintilesims. each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. quintilesims has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. as a global leader in protecting individual patient privacy, quintilesims uses healthcare data to deliver critical, real-world disease and treatment insights. to learn more, visit www.quintilesims.com
Company profile
Ticker
IQV
Exchange
Website
CEO
Ari Bousbib
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb • SomaLogic ...
Former names
Quintiles IMS Holdings, Inc., Quintiles Transnational Holdings Inc.
SEC CIK
Corporate docs
Subsidiaries
159 Solutions, LLC • 159 Technology • AECIO IT Solutions India Private Ltd. • AHM Global Services, LLC • AIT Bioscience LLC • Albatross Financial Solutions Limited • ALIMED Egeszsegugyi Szolgaltato Kft. • Allcare Plus Pharmacy LLC • Apuro.com K.K. • Ardentia International Limited ...
IRS number
271341991
IQV stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
17 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Feb 24
DEFA14A
Additional proxy soliciting materials
23 Feb 24
DEF 14A
Definitive proxy
23 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Results of Operations and Financial Condition
14 Feb 24
424B3
Prospectus supplement
25 Jan 24
EFFECT
Notice of effectiveness
23 Jan 24
CORRESP
Correspondence with SEC
18 Jan 24
Transcripts
IQV
Earnings call transcript
2023 Q4
14 Feb 24
IQV
Earnings call transcript
2023 Q3
1 Nov 23
IQV
Earnings call transcript
2023 Q2
1 Aug 23
IQV
Earnings call transcript
2023 Q1
27 Apr 23
IQV
Earnings call transcript
2022 Q4
10 Feb 23
IQV
Earnings call transcript
2022 Q3
26 Oct 22
IQV
Earnings call transcript
2022 Q2
21 Jul 22
IQV
Earnings call transcript
2022 Q1
27 Apr 22
IQV
Earnings call transcript
2021 Q4
15 Feb 22
IQV
Earnings call transcript
2021 Q3
21 Oct 21
Latest ownership filings
4
ARI BOUSBIB
4 Mar 24
4
W RICHARD STAUB
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Kevin C Knightly
1 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
28 Feb 24
4
Eric Sherbet
21 Feb 24
4
Kevin C Knightly
21 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.22 bn | 1.22 bn | 1.22 bn | 1.22 bn | 1.22 bn | 1.22 bn |
Cash burn (monthly) | 52.67 mm | 4.17 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 362.20 mm | 28.65 mm | n/a | n/a | n/a | n/a |
Cash remaining | 861.80 mm | 1.20 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 16.4 | 286.9 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
86.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 908 |
Opened positions | 109 |
Closed positions | 86 |
Increased positions | 338 |
Reduced positions | 329 |
13F shares | Current |
---|---|
Total value | 30.44 tn |
Total shares | 157.60 mm |
Total puts | 293.90 k |
Total calls | 273.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 20.37 mm | $4.01 tn |
BLK Blackrock | 14.89 mm | $2.93 tn |
STT State Street | 8.07 mm | $1.59 tn |
Harris Associates L P | 7.90 mm | $1.55 tn |
Alliancebernstein | 5.65 mm | $1.11 tn |
Geode Capital Management | 3.94 mm | $774.41 bn |
MS Morgan Stanley | 3.73 mm | $733.15 bn |
FMR | 3.32 mm | $652.69 bn |
Canada Pension Plan Investment Board | 3.09 mm | $608.53 bn |
Lazard Asset Management | 2.89 mm | $568.46 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Bousbib Ari | Common Stock | Sale back to company | Dispose D | No | No | 249.97 | 11,169 | 2.79 mm | 785,583 |
1 Mar 24 | Bousbib Ari | Common Stock | Sell | Dispose S | No | No | 251.03 | 15,417 | 3.87 mm | 796,752 |
1 Mar 24 | Bousbib Ari | Common Stock | Sell | Dispose S | No | No | 250.05 | 16,261 | 4.07 mm | 812,169 |
1 Mar 24 | Bousbib Ari | Common Stock | Option exercise | Acquire M | No | No | 65.16 | 42,847 | 2.79 mm | 828,430 |
1 Mar 24 | Bousbib Ari | Stock Appreciation Right Common Stock | Option exercise | Dispose M | No | No | 65.16 | 42,847 | 2.79 mm | 40,000 |
29 Feb 24 | W Richard Staub | Common Stock | Sell | Dispose S | No | No | 249.08 | 2,068 | 515.10 k | 15,945 |
29 Feb 24 | W Richard Staub | Common Stock | Sell | Dispose S | No | No | 248.33 | 3,062 | 760.39 k | 18,013 |
29 Feb 24 | W Richard Staub | Common Stock | Sell | Dispose S | No | No | 247.33 | 8,970 | 2.22 mm | 21,075 |
28 Feb 24 | Kevin C Knightly | Common Stock | Sale back to company | Dispose D | No | No | 251.02 | 4,599 | 1.15 mm | 652 |
28 Feb 24 | Kevin C Knightly | Common Stock | Sell | Dispose S | No | No | 250.83 | 2,182 | 547.31 k | 5,251 |
News
Salesforce & IQVIA Expand Partnership: Life Sciences Cloud Gets A Superpower Boost
9 Apr 24
IQVIA and Salesforce Expand Global Partnership To Accelerate The Development Of Life Sciences Cloud
8 Apr 24
Peering Into IQVIA Hldgs's Recent Short Interest
29 Mar 24
Peering Into IQVIA Hldgs's Recent Short Interest
13 Mar 24
Truist Securities Maintains Buy on IQVIA Hldgs, Raises Price Target to $297
27 Feb 24
Press releases
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
15 Apr 24
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
8 Apr 24
IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024
6 Mar 24
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
23 Feb 24
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
14 Feb 24